Physician profile
Taylor R Tendrich
NPI 1912460130
$3,044.08
in general payments reported to CMS, 2019-2025
13 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $432 · 2022: $1,459 · 2023: $179 · 2024: $681 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,153.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Southern Edge Orthopaedics, INC. | $1,200.00 | 2022 | |
| Smith+Nephew, INC. | $552.67 | 2021-2024 | Stravix, Grafix Pl, Collagenase Santyl |
| Stryker Corporation | $474.42 | 2023-2025 | Vitoss, Variax, Hoffmann |
| Kerecis Limited | $293.24 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Biocomposites INC | $144.31 | 2024 | |
| Horizon Therapeutics Plc | $108.51 | 2021 | |
| Biotissue Holdings INC. | $100.00 | 2022 | |
| Paratek Pharmaceuticals, INC. | $48.84 | 2025 | Nuzyra |
| Treace Medical Concepts, INC. | $42.77 | 2023-2024 | |
| Vertex Pharmaceuticals Incorporated | $29.90 | 2024 | |
| Organogenesis INC. | $22.16 | 2024 | |
| Mimedx Group, INC. | $13.67 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $13.59 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Tendrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.